Results for bethesda translation from English to Swedish

Bethesda
Bethesda

Bethesda
BethesdaCity in Maryland USA

Fledermausquartier ‘Haus Bethesda’
Fledermausquartier ”Haus Bethesda”

the Bethesda group of bacteria
Citrobacter freundii

Inhibitory activity, as measured by the modified Bethesda assay, was not detected in this patient.
Inhibitorisk aktivitet, enligt mätning med det modifierade Bethesda-testet, detekterades inte hos denna patient.

Inhibitor titres of up to 29 Bethesda units were recorded at baseline yet subjects responded positively to OBIZUR.
Hämmande titrer på upp till 29 Bethesda-enheter har registrerats vid baslinjen, men ändå har patienterna svarat positivt på OBIZUR.

Inhibitory antibodies against OBIZUR were measured using a modification of the Nijmegen variation of the Bethesda assay method.
Hämmande antikroppar mot OBIZUR mättes med en modifiering av Nijmegen-variationen av Bethesda-analysmetoden.

It is recommended that treatment should be based on clinical judgement and not based on detection of inhibitory antibodies by the Bethesda assay.
Det rekommenderas att behandlingen baseras på klinisk bedömning och inte på detektion av hämmande antikroppar genom Bethesda-analys.

in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 Bethesda Units (BU)
hos patienter med medfödd hemofili med antikroppar mot koagulationsfaktorer VIII eller IX > 5 Bethesda- enheter

Now there is at Jerusalem by the sheep market a pool, which is called in the Hebrew tongue Bethesda, having five porches.
Vid Fårporten i Jerusalem ligger en damm, på hebreiska kallad Betesda, och invid den finnas fem pelargångar.

These inhibitors are invariably IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Modified Bethesda Units (BU) per ml of plasma.
Dessa inhibitorer är undantagslöst IgG immunglobuliner som riktas mot den prokoagulerande aktiviteten hos faktor VIII, och kvantifieras i modifierade Bethesda- enheter (BU) per ml plasma.

2 One adult subject had a positive anti-Factor VIII antibody test result coincident with a single measurement of a neutralising antibody titre of 0.73 Bethesda Units/mL at Week 14.
2 En vuxen försöksperson hade ett positivt testresultat för anti-faktor VIII-antikroppar samtidigt med en enstaka mätning av neutraliserande antikroppstiter på 0,73 Bethesda-enheter/ml vecka 14.

These inhibitors are usually IgGs directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma using the modified Bethesda assay.
Dessa inhibitorer är vanligtvis IgG riktade mot den prokoagulerande effekten hos faktor VIII, vilken kvantifieras i Bethesda- enheter (BE) per ml plasma med det modifierade Bethesda- testet.

Data from clinical trials indicated that if inhibitors are present at levels less than 10 Bethesda Units (BUs), administration of additional antihaemophilic factor may neutralise the inhibitors.
Uppgifter från kliniska prövningar tyder på att om inhibitornivån understiger 10 Bethesda- enheter (BU) kan tillförsel av ytterligare koagulationsfaktor neutralisera inhibitorerna.

As with all coagulation factor VIII products, patients are to be monitored for the development of inhibitors that are to be titrated in Bethesda Units (BUs) using the Nijmegen modification of the Bethesda assay.
Liksom med alla koagulationsfaktor VIII- produkter ska patienten övervakas för utveckling av inhibitorer som ska titreras i Bethesda Units (BU) med hjälp av Nijmegenmodifierad Bethesdametod.

These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BUs) per ml of plasma using the Nijmegen modification of the Bethesda assay.
Dessa inhibitorer är vanligtvis IgG immunoglobuliner riktade mot koagulationsfaktor VIII- aktiviteten, som kvantifieras i Bethesda Units (BU) per ml plasma med hjälp av den Nijmegenmodifierade Bethesdametoden.

Since during clinical studies one PTP treated with BeneFIX developed a clinically relevant low responding inhibitor and experience on antigenicity with recombinant factor IX is still limited, patients treated with BeneFIX should be carefully monitored for the development of factor IX inhibitors that should be titrated in Bethesda Units using appropriate biological testing.
Detta bör göras genom titrering i Bethesda- enheter med användning av lämpligt biologisk test.

These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BUs) per ml of plasma using the Nijmegen modification of the Bethesda assay.
Risken att utveckla inhibitorer är korrelerad till

If the inhibitor is present at levels less than 10 Bethesda Units (BU) per mL, administration of additional recombinant coagulation factor VIII may neutralise the inhibitor and permit continued clinically effective therapy with KOGENATE Bayer.
Om inhibitorkoncentrationen är lägre än 10 Bethesda-enheter (BU) per ml kan tillförsel av ytterligare rekombinant koagulationsfaktor VIII neutralisera inhibitorn och medge fortsatt kliniskt effektiv behandling med KOGENATE Bayer.

If the inhibitor is present at levels less than 10 Bethesda Units (BU) per ml, administration of additional recombinant coagulation factor VIII may neutralise the inhibitor and permit continued clinically effective therapy with Helixate NexGen.
Om inhibitorkoncentrationen är lägre än 10 Bethesda-enheter (BU) per ml kan tillförsel av ytterligare rekombinant koagulationsfaktor VIII neutralisera inhibitorn och medge fortsatt kliniskt effektiv behandling med Helixate NexGen.